Transdermal delivery of pharmaceutical agents has proven effective for drugs that are able to move across the skin barrier. For example, small amounts of nicotine can be delivered over extended periods with transdermal patches that suspend the nicotine in an ethylene vinyl acetate (EVA) copolymer. See, e.g., Nicoderm-CQ® by GlaxoSmithKline (Brentford, UK). Most of the commercially-available transdermal patches contain a matrix with only one drug, or a combination of drugs that are compatible for storage, such as oxycodone and tocopherol. See, e.g., TPM/Oxycodone patch from Phosphagenics, Ltd. (Melbourne, AU). Nonetheless, the efficacy of multi-component patches may degrade with time as the components interact. See, e.g., reports of crystallization in rotigotine transdermal patches (Nuepro®, UCB, Inc., Smyrna, Ga.).
Because there are a number of medications that are best administered in combination, there is a need for a simple (and inexpensive) delivery system that allows for the simultaneous delivery of multiple active components from the same transdermal system. Additionally, it would be beneficial if the delivery could be accomplished on demand sometime after the transdermal patch has been affixed to the skin.
The invention addresses these needs by providing a transdermal delivery system whereby active molecules can be administered with an electric potential. The systems of the invention allow for the delivery of different types, different concentrations, and/or different volumes of active molecules from the same delivery system. The actives may be pharmaceutical compounds, vitamins, adjuvants, biologics, penetrants, vaccines, or genetic material (i.e., DNA or RNA). The actives may be water soluble or water insoluble.
Thus, in one aspect the invention is an active molecule delivery system including a plurality of microcells. The microcells may be square, round, or polygonal, such as a honeycomb structure. Each microcell includes an opening that is spanned by a porous conductive layer. The porous conductive layer may comprise, e.g., a conductive grid or mesh. The porous conductive layer may comprise a mat of conductive filaments, such as made from carbon, e.g., carbon nanotubes, silver, nickel, or gold. The porous conductive layer may comprise a porous conductive film, e.g., a film coated with graphite. The delivery system may additionally comprise a porous diffusion layer which may be constructed from a variety of materials, such acrylate, methacrylate, polycarbonate, polyvinyl alcohol, cellulose, poly(N-isopropylacrylamide) (PNIPAAm), poly(lactic-co-glycolic acid) (PLGA), polyvinylidene chloride, acrylonitrile, amorphous nylon, oriented polyester, terephthalate, polyvinyl chloride, polyethylene, polypropylene, polybutylene, polyisobutylene, or polystyrene. The porous conductive layer and the porous diffusion layer may be separate layers or they may be integrated into a single layer. Typically, each microcell has a volume greater than 100 nL, and the porous diffusion layer has an average pore size of between 1 nm and 100 nm.
In one aspect the active molecule delivery system allows different actives or concentrations to be delivered on demand. Such systems may include a system of independently-addressable electrodes disposed adjacent to microcells but opposite to the porous conductive layer. The electrodes above and below the microcells can be used to cause the electrophoretic delivery of the active or to cause the motion of an electrophoretic particle away from a porous layer, thereby allowing the release of the desired active. In one embodiment, the system includes at least first and second microcells, wherein the first microcell includes a first active molecule and the second microcell includes a second active molecule, which is different from the first active molecule. In another embodiment, the system includes at least first and second microcells, wherein the first microcell includes a first concentration of an active molecule and the second microcell includes a second concentration of the active molecule, which is different from the first concentration. In another embodiment, the system includes at least first and second microcells, wherein the average pore size of the porous conductive layer over the opening of the first microcell is different from the average pore size of the porous diffusion layer over the opening of the second microcell. In addition to varying the type and concentration of active molecules, it is also possible to prepare a system including an active and another useful compound such as a vitamin, adjuvant, etc. Other combinations of active molecules, agents, and concentrations will be evident to one of skill in the art.
In some embodiments, an active molecule is distributed in a biocompatible non-polar liquid, such as an oil, such as vegetable, fruit, or nut oil. In other embodiments, the active molecules are distributed in an aqueous liquid, such as water or an aqueous buffer. The mixtures may also include charge control agents, surfactants, nutrients, and adjuvants. Typically, the active molecule is a pharmaceutical compound, however systems of the invention can be used to deliver hormones, nutraceuticals, proteins, nucleic acids, antibodies, or vaccines.
In some embodiments, the active molecule delivery system will include a separate sealing layer. The sealing layer typically is used to seal the openings of the microcells, and is located between the openings of the microcells and the porous conductive layer. The sealing layer may be, for example, methylcellulose, hydroxymethylcellulose, an acrylate, a methacrylate, a polycarbonate, a polyvinyl alcohol, cellulose, poly(N-isopropylacrylamide) (PNIPAAm), poly(lactic-co-glycolic acid) (PLGA), polyvinylidene chloride, acrylonitrile, amorphous nylon, oriented polyester, terephthalate, polyvinyl chloride, polyethylene, polypropylene, polybutylene, polyisobutylene, or polystyrene.
The invention provides an active molecule delivery system whereby active molecules can be released on demand and/or a variety of different active molecules can be delivered from the same system and/or different concentrations of active molecules can be delivered from the same system. The invention is well-suited for delivering pharmaceuticals to patients transdermally, however the invention may be used to deliver active ingredients, generally. For example, the invention can deliver tranquilizing agents to a horse during transport. The active delivery system includes a first electrode, a plurality of microcells, and a porous conductive layer. The microcells are filled with a medium including active molecules. The microcells include an opening, and the opening is spanned by the porous conductive layer. The microcell arrays may be loaded with different active ingredients, thereby providing a mechanism to deliver different, or complimentary, active ingredients on demand.
In addition to more conventional applications, such as transdermal delivery of pharmaceutical compounds, the active molecule delivery system may be the basis for delivering agricultural nutrients. The active molecule delivery systems can also be incorporated into the structural walls of smart packing. Such delivery systems makes it possible to have long term release of antioxidants into a package containing fresh vegetables. This “smart” packaging will dramatically improve the shelf life of certain foods, and it will only require the amount of antioxidant necessary to maintain freshness until the package is opened. Thus, the same packaging can be used for food that is distributed locally, across the country, or around the globe.
The invention also provides a system for simple and low cost delivery of “cocktails” of active molecules on demand. Such a delivery system may be used, for example, as an emergency delivery system for a person undergoing an allergic reaction. The system may include epinephrine, as well as antihistamines. The device can be applied and then triggered to cause the actives to be quickly passed through the skin. The system may be particularly effective as a back-up system for small children who may be exposed to life-threatening allergens while on a field trip, etc. A parent can affix the delivery system to the child with instructions to activate the device in the event of, e.g., a bee sting. Because the device is relatively simple, compliance with proper delivery protocols will be greater than, e.g., an epipen.
An overview of an active molecule delivery system 100 is shown in
As shown in
As shown in
Additional functionality can be introduced into the active molecule delivery system by preloading one or more layers outside of the layer of microcells 301 with additional charged actives. The additional charged actives can be the same actives, or different actives, thereby allowing for baseline drug delivery or delivery of drug combinations. For example, the system may include charged actives 213A in a sealing layer 212, as shown in
Of course, a variety of combinations are possible, and varying microcells might include pharmaceuticals, nutraceuticals, adjuvants, vitamins, penetrants, or vaccines. Furthermore, the arrangement of the microcells may not be distributed. Rather the microcells may be filled in clusters, which makes filling and sealing more straightforward. In other embodiments, smaller microcell arrays may be filled with the same medium, i.e., having the same active molecule at the same concentration, and then the smaller arrays assembled into a larger array to make a delivery system of the invention. All of these combinations may be further augmented with the addition of one or more layers that includes additional pharmaceuticals, nutraceuticals, adjuvants, vitamins, penetrants, or vaccines.
Techniques for Constructing Microcells.
Microcells may be formed either in a batchwise process or in a continuous roll-to-roll process as disclosed in U.S. Pat. No. 6,933,098. The latter offers a continuous, low cost, high throughput manufacturing technology for production of compartments for use in a variety of applications including active molecule delivery and electrophoretic displays. Microcell arrays suitable for use with the invention can be created with microembossing, as illustrated in
The thermoplastic or thermoset precursor for the preparation of the microcells may be multifunctional acrylate or methacrylate, vinyl ether, epoxide and oligomers or polymers thereof, and the like. A combination of multifunctional epoxide and multifunctional acrylate is also very useful to achieve desirable physico-mechanical properties. A crosslinkable oligomer imparting flexibility, such as urethane acrylate or polyester acrylate, may be added to improve the flexure resistance of the embossed microcells. The composition may contain polymer, oligomer, monomer and additives or only oligomer, monomer and additives. The glass transition temperatures (or Tg) for this class of materials usually range from about −70° C. to about 150° C., preferably from about −20° C. to about 50° C. The microembossing process is typically carried out at a temperature higher than the Tg. A heated male mold or a heated housing substrate against which the mold presses may be used to control the microembossing temperature and pressure.
As shown in
Prior to applying a UV curable resin composition, the mold may be treated with a mold release to aid in the demolding process. The UV curable resin may be degassed prior to dispensing and may optionally contain a solvent. The solvent, if present, readily evaporates. The UV curable resin is dispensed by any appropriate means such as, coating, dipping, pouring or the like, over the male mold. The dispenser may be moving or stationary. A conductor film is overlaid the UV curable resin. Pressure may be applied, if necessary, to ensure proper bonding between the resin and the plastic and to control the thickness of the floor of the microcells. The pressure may be applied using a laminating roller, vacuum molding, press device or any other like means. If the male mold is metallic and opaque, the plastic substrate is typically transparent to the actinic radiation used to cure the resin. Conversely, the male mold can be transparent and the plastic substrate can be opaque to the actinic radiation. To obtain good transfer of the molded features onto the transfer sheet, the conductor film needs to have good adhesion to the UV curable resin which should have a good release property against the mold surface.
Photolithography.
Microcells can also be produced using photolithography. Photolithographic processes for fabricating a microcell array are illustrated in
In the photomask 46 in
As shown in
Imagewise Exposure.
Still another alternative method for the preparation of the microcell array of the invention by imagewise exposure is illustrated in
The microcells may be constructed from thermoplastic elastomers, which have good compatibility with the microcells and do not interact with the electrophoretic media. Examples of useful thermoplastic elastomers include ABA, and (AB)n type of di-block, tri-block, and multi-block copolymers wherein A is styrene, α-methylstyrene, ethylene, propylene or norbornene; B is butadiene, isoprene, ethylene, propylene, butylene, dimethylsiloxane or propylene sulfide; and A and B cannot be the same in the formula. The number, n, is ≥1, preferably 1-10. Particularly useful are di-block or tri-block copolymers of styrene or ox-methylstyrene such as SB (poly(styrene-b-butadiene)), SBS (poly(styrene-b-butadiene-b-styrene)), SIS (poly(styrene-b-isoprene-b-styrene)), SEBS (poly(styrene-b-ethylene/butylenes-b-stylene)) poly(styrene-b-dimethylsiloxane-b-styrene), poly((α-methylstyrene-b-isoprene), poly(α-methylstyrene-b-isoprene-b-α-methylstyrene), poly(α-methylstyrene-b-propylene sulfide-b-α-methylstyrene), poly(α-methylstyrene-b-dimethylsiloxane-b-α-methylstyrene). Commercially available styrene block copolymers such as Kraton D and G series (from Kraton Polymer, Houston, Tex.) are particularly useful. Crystalline rubbers such as poly(ethylene-co-propylene-co-5-methylene-2-norbornene) or EPDM (ethylene-propylene-diene terpolymer) rubbers such as Vistalon 6505 (from Exxon Mobil, Houston, Tex.) and their grafted copolymers have also been found very useful.
The thermoplastic elastomers may be dissolved in a solvent or solvent mixture which is immiscible with the display fluid in the microcells and exhibits a specific gravity less than that of the display fluid. Low surface tension solvents are preferred for the overcoating composition because of their better wetting properties over the microcell walls and the electrophoretic fluid. Solvents or solvent mixtures having a surface tension lower than 35 dyne/cm are preferred. A surface tension of lower than 30 dyne/cm is more preferred. Suitable solvents include alkanes (preferably C6-12 alkanes such as heptane, octane or Isopar solvents from Exxon Chemical Company, nonane, decane and their isomers), cycloalkanes (preferably C6-12 cycloalkanes such as cyclohexane and decalin and the like), alkylbezenes (preferably mono- or di-C1-6 alkyl benzenes such as toluene, xylene and the like), alkyl esters (preferably C2-5 alkyl esters such as ethyl acetate, isobutyl acetate and the like) and C3-5 alkyl alcohols (such as isopropanol and the like and their isomers). Mixtures of alkylbenzene and alkane are particularly useful.
In addition to polymer additives, the polymer mixtures may also include wetting agents (surfactants). Wetting agents (such as the FC surfactants from 3M Company, Zonyl fluorosurfactants from DuPont, fluoroacrylates, fluoromethacrylates, fluoro-substituted long chain alcohols, perfluoro-substituted long chain carboxylic acids and their derivatives, and Silwet silicone surfactants from OSi, Greenwich, Conn.) may also be included in the composition to improve the adhesion of the sealant to the microcells and provide a more flexible coating process. Other ingredients including crosslinking agents (e.g., bisazides such as 4,4′-diazidodiphenylmethane and 2,6-di-(4′-azidobenzal)-4-methylcyclohexanone), vulcanizers (e.g., 2-benzothiazolyl disulfide and tetramethylthiuram disulfide), multifunctional monomers or oligomers (e.g., hexanediol, diacrylates, trimethylolpropane, triacrylate, divinylbenzene, diallylphthalene), thermal initiators (e.g., dilauroryl peroxide, benzoyl peroxide) and photoinitiators (e.g., isopropyl thioxanthone (ITX), Irgacure 651 and Irgacure 369 from Ciba-Geigy) are also highly useful to enhance the physico-mechanical properties of the sealing layer by crosslinking or polymerization reactions during or after the overcoating process.
After the microcells are produced, they are filled with appropriate mixtures of active molecules. The microcell array 60 may be prepared by any of the methods described above. As shown in cross-section in
The microcells are next filled with a mixture 64 including active molecules 65. As shown in
The microcells may be filled using a variety of techniques. In some embodiments, where a large number of neighboring microcells are to be filled with an identical mixture, blade coating may be used to fill the microcells to the depth of the microcell walls 61. In other embodiments, where a variety of different mixtures are to be filled in a variety of nearby microcell, inkjet-type microinjection can be used to fill the microcells. In yet other embodiments, microneedle arrays may be used to fill an array of microcells with the correct mixtures. The filling may be done in a one-step, or a multistep process. For example, all of the cells may be partially filled with an amount of solvent. The partially filled microcells are then filled with a second mixture including the one or more active molecules to be delivered.
As shown in
In alternate embodiments, a variety of individual microcells may be filled with the desired mixture by using iterative photolithography. The process typically includes coating an array of empty microcells with a layer of positively working photoresist, selectively opening a certain number of the microcells by imagewise exposing the positive photoresist, followed by developing the photoresist, filling the opened microcells with the desired mixture, and sealing the filled microcells by a sealing process. These steps may be repeated to create sealed microcells filled with other mixtures. This procedure allows for the formation of large sheets of microcells having the desired ratio of mixtures or concentrations.
After the microcells 60 are filled, the sealed array may be laminated with a finishing layer 68 that is also porous to the active molecules, preferably by pre-coating the finishing layer 68 with an adhesive layer which may be a pressure sensitive adhesive, a hot melt adhesive, or a heat, moisture, or radiation curable adhesive. The laminate adhesive may be post-cured by radiation such as UV through the top conductor film if the latter is transparent to the radiation. In some embodiments, a biocompatible adhesive 67 is then laminated to the assembly. The biocompatible adhesive 67 will allow active molecules to pass through while keeping the device mobile on a user. Suitable biocompatible adhesives are available from 3M (Minneapolis, Minn.).
In order for the porous conductive layer to drive all the charged particles inside microcell, the sealing layer will preferred to have lower electrical resistivity than the EPD requirement, preferably less than 109 ohm·cm. If the resistivity of the sealing layer is higher, the local field strength within the microcells may not be sufficient to move the charge particles away from the porous diffusion layer, etc. When the sealing resistance is low, the fringing field is wide enough to cover the areas without electrodes and therefore all of the charged particles inside microcell will be driven.
Once the delivery system has been constructed, it may be covered with an encapsulating backing to provide protection against physical shock. The encapsulating backing may also include adhesives to make sure that the active molecule delivery system stays affixed, e.g., to a patient's back. The encapsulating backing may also include aesthetic coloring or fun designs for children. The sealing layer is semi-porous in most applications, that is, the sealing layer to form a barrier that prevents any fluid contained within the microcell from escaping while the actives are allowed to pass. The sealing layer 78 may be constructed from any of the materials listed above with respect to the porous diffusion layer. In addition, the sealing layer can also be constructed from poly(vinylpyrrolidone), hydroxymethylcellulose, or polyvinyl alcohols.
Porous Conductive Layer.
A variety of constructions are suitable as porous conductive layers. For example, the porous electrode can be a conductive metal mesh or grid 740 as shown in
An additional benefit of using a continuous film of porous conductive material is that the active delivery devices can be manufactured in a roll-to-roll process, as shown in
Thus the invention provides for an active molecule delivery system including a plurality of microcells. The microcells may include differing active molecules, or differing concentrations of active molecules. The microcells include an opening that is spanned by a porous conductive layer in addition to a porous diffusion layer. This disclosure is not limiting, and other modifications to the invention, not described, but self-evident to one of skill in the art, are to be included in the scope of the invention.
This application claims priority to U.S. Provisional Patent Application No. 62/585,663, filed Nov. 14, 2017 which is incorporated by reference in its entirety, along with all other patents and patent applications disclosed herein.
Number | Name | Date | Kind |
---|---|---|---|
3756693 | Ota | Sep 1973 | A |
3892568 | Ota | Jul 1975 | A |
4298448 | Muller et al. | Nov 1981 | A |
4559222 | Enscore et al. | Dec 1985 | A |
4640689 | Sibalis | Feb 1987 | A |
4734090 | Sibalis | Mar 1988 | A |
5125894 | Phipps et al. | Jun 1992 | A |
5135479 | Sibalis et al. | Aug 1992 | A |
5378574 | Winnik et al. | Jan 1995 | A |
5486362 | Kitchell et al. | Jan 1996 | A |
5533995 | Corish et al. | Jul 1996 | A |
5591767 | Mohr et al. | Jan 1997 | A |
5603693 | Frenkel et al. | Feb 1997 | A |
5658592 | Tanihara et al. | Aug 1997 | A |
5797898 | Santini, Jr. et al. | Aug 1998 | A |
5931804 | Sibalis | Aug 1999 | A |
5980719 | Cherukuri et al. | Nov 1999 | A |
5980943 | Ayer et al. | Nov 1999 | A |
6017584 | Albert et al. | Jan 2000 | A |
6123861 | Santini, Jr. et al. | Sep 2000 | A |
6198809 | DiSanto et al. | Mar 2001 | B1 |
6337761 | Rogers et al. | Jan 2002 | B1 |
6373461 | Hasegawa et al. | Apr 2002 | B1 |
6486866 | Kuwahara et al. | Nov 2002 | B1 |
6491666 | Santini, Jr. et al. | Dec 2002 | B1 |
6517618 | Foucher et al. | Feb 2003 | B2 |
6521191 | Schenk et al. | Feb 2003 | B1 |
6525866 | Lin et al. | Feb 2003 | B1 |
6538801 | Jacobson et al. | Mar 2003 | B2 |
6545797 | Chen et al. | Apr 2003 | B2 |
6564093 | Ostrow et al. | May 2003 | B1 |
6565532 | Yuzhakov et al. | May 2003 | B1 |
6600534 | Tanaka et al. | Jul 2003 | B1 |
6650462 | Katase | Nov 2003 | B2 |
6664944 | Albert et al. | Dec 2003 | B1 |
6680726 | Gordon, II et al. | Jan 2004 | B2 |
6693620 | Herb et al. | Feb 2004 | B1 |
6704133 | Gates et al. | Mar 2004 | B2 |
6724521 | Nakao et al. | Apr 2004 | B2 |
6729718 | Goto et al. | May 2004 | B2 |
6751007 | Liang et al. | Jun 2004 | B2 |
6751008 | Liang et al. | Jun 2004 | B2 |
6757560 | Fischer et al. | Jun 2004 | B1 |
6781745 | Chung et al. | Aug 2004 | B2 |
6788452 | Liang et al. | Sep 2004 | B2 |
6829078 | Liang et al. | Dec 2004 | B2 |
6850357 | Kaneko et al. | Feb 2005 | B2 |
6864875 | Drzaic et al. | Mar 2005 | B2 |
6876486 | Hiraoka et al. | Apr 2005 | B2 |
6914714 | Chen et al. | Jul 2005 | B2 |
6930818 | Liang et al. | Aug 2005 | B1 |
6933098 | Chan-Park et al. | Aug 2005 | B2 |
6947203 | Kanbe | Sep 2005 | B2 |
6967762 | Machida et al. | Nov 2005 | B2 |
6972893 | Chen et al. | Dec 2005 | B2 |
6980855 | Cho | Dec 2005 | B2 |
6987503 | Inoue | Jan 2006 | B2 |
6987605 | Liang et al. | Jan 2006 | B2 |
7009756 | Kishi et al. | Mar 2006 | B2 |
7019889 | Katase | Mar 2006 | B2 |
7034987 | Schlangen | Apr 2006 | B2 |
7038655 | Herb et al. | May 2006 | B2 |
7038656 | Liang et al. | May 2006 | B2 |
7038670 | Liang et al. | May 2006 | B2 |
7046228 | Liang et al. | May 2006 | B2 |
7050218 | Kanbe | May 2006 | B2 |
7052571 | Wang et al. | May 2006 | B2 |
7057600 | Goden | Jun 2006 | B2 |
7057798 | Ukigaya | Jun 2006 | B2 |
7075502 | Drzaic et al. | Jul 2006 | B1 |
7116466 | Whitesides et al. | Oct 2006 | B2 |
7167155 | Albert et al. | Jan 2007 | B1 |
7226550 | Hou et al. | Jun 2007 | B2 |
7229556 | Hinds, III et al. | Jun 2007 | B1 |
7259744 | Arango et al. | Aug 2007 | B2 |
7271947 | Liang et al. | Sep 2007 | B2 |
7279064 | Daniel et al. | Oct 2007 | B2 |
7283119 | Kishi | Oct 2007 | B2 |
7292386 | Kanbe | Nov 2007 | B2 |
7303818 | Minami | Dec 2007 | B2 |
7304987 | James et al. | Dec 2007 | B1 |
7312916 | Pullen et al. | Dec 2007 | B2 |
7315758 | Kwiatkowski et al. | Jan 2008 | B2 |
7342556 | Oue et al. | Mar 2008 | B2 |
7345810 | Chopra et al. | Mar 2008 | B2 |
7352353 | Albert et al. | Apr 2008 | B2 |
7365732 | Matsuda et al. | Apr 2008 | B2 |
7382351 | Kishi | Jun 2008 | B2 |
7383083 | Fischer | Jun 2008 | B2 |
7385751 | Chen et al. | Jun 2008 | B2 |
7392080 | Eppstein et al. | Jun 2008 | B2 |
7411719 | Paolini, Jr. et al. | Aug 2008 | B2 |
7417787 | Chopra et al. | Aug 2008 | B2 |
7420549 | Jacobson et al. | Sep 2008 | B2 |
7433113 | Chopra et al. | Oct 2008 | B2 |
7443570 | Chopra et al. | Oct 2008 | B2 |
7474295 | Matsuda | Jan 2009 | B2 |
7492505 | Liang et al. | Feb 2009 | B2 |
7495821 | Yamakita et al. | Feb 2009 | B2 |
7502162 | Lin et al. | Mar 2009 | B2 |
7537590 | Santini, Jr. et al. | May 2009 | B2 |
7545557 | Iftime et al. | Jun 2009 | B2 |
7548291 | Lee et al. | Jun 2009 | B2 |
7557981 | Liang et al. | Jul 2009 | B2 |
7580025 | Nakai et al. | Aug 2009 | B2 |
7604628 | Santini, Jr. et al. | Oct 2009 | B2 |
7605972 | Kawai et al. | Oct 2009 | B2 |
7609435 | Moriyama et al. | Oct 2009 | B2 |
7611481 | Cleary et al. | Nov 2009 | B2 |
7626185 | Krak et al. | Dec 2009 | B2 |
7636076 | Hung et al. | Dec 2009 | B2 |
7652656 | Chopra et al. | Jan 2010 | B2 |
7656576 | Suwabe et al. | Feb 2010 | B2 |
7667684 | Jacobson et al. | Feb 2010 | B2 |
7679599 | Kawai | Mar 2010 | B2 |
7684108 | Wang et al. | Mar 2010 | B2 |
7686463 | Goto | Mar 2010 | B2 |
7715088 | Liang et al. | May 2010 | B2 |
7760419 | Lee | Jul 2010 | B2 |
7782292 | Miyasaka et al. | Aug 2010 | B2 |
7791789 | Albert et al. | Sep 2010 | B2 |
7800813 | Wu et al. | Sep 2010 | B2 |
7808696 | Lee et al. | Oct 2010 | B2 |
7821702 | Liang et al. | Oct 2010 | B2 |
7830592 | Sprague et al. | Nov 2010 | B1 |
7839564 | Whitesides et al. | Nov 2010 | B2 |
7848009 | Machida et al. | Dec 2010 | B2 |
7852547 | Kim | Dec 2010 | B2 |
7852548 | Roh | Dec 2010 | B2 |
7892221 | Santini, Jr. et al. | Feb 2011 | B2 |
7907327 | Jang et al. | Mar 2011 | B2 |
7910175 | Webber | Mar 2011 | B2 |
7911681 | Ikegami et al. | Mar 2011 | B2 |
7952790 | Honeyman | May 2011 | B2 |
7956841 | Albert et al. | Jun 2011 | B2 |
7982941 | Lin et al. | Jul 2011 | B2 |
8040594 | Paolini, Jr. et al. | Oct 2011 | B2 |
8054526 | Bouchard | Nov 2011 | B2 |
8067305 | Zafiropoulo et al. | Nov 2011 | B2 |
8072675 | Lin et al. | Dec 2011 | B2 |
8081375 | Komatsu et al. | Dec 2011 | B2 |
8089686 | Addington et al. | Jan 2012 | B2 |
8095213 | Sexton | Jan 2012 | B1 |
8098418 | Paolini, Jr. et al. | Jan 2012 | B2 |
8115729 | Danner et al. | Feb 2012 | B2 |
8120838 | Lin et al. | Feb 2012 | B2 |
8159636 | Sun et al. | Apr 2012 | B2 |
8164823 | Ikegami et al. | Apr 2012 | B2 |
8169690 | Lin et al. | May 2012 | B2 |
8174492 | Kim et al. | May 2012 | B2 |
8213076 | Albert et al. | Jul 2012 | B2 |
8237892 | Sprague et al. | Aug 2012 | B1 |
8243013 | Sprague et al. | Aug 2012 | B1 |
8257324 | Prausnitz et al. | Sep 2012 | B2 |
8355196 | Yan et al. | Jan 2013 | B2 |
8363299 | Paolini, Jr. et al. | Jan 2013 | B2 |
8395836 | Lin | Mar 2013 | B2 |
8403915 | Santini, Jr. et al. | Mar 2013 | B2 |
8422116 | Sprague et al. | Apr 2013 | B2 |
8440222 | Hausner et al. | May 2013 | B2 |
8441713 | Kawashima et al. | May 2013 | B2 |
8441714 | Paolini, Jr. et al. | May 2013 | B2 |
8441716 | Paolini, Jr. et al. | May 2013 | B2 |
8466852 | Drzaic et al. | Jun 2013 | B2 |
8477404 | Moriyama et al. | Jul 2013 | B2 |
8477405 | Ishii et al. | Jul 2013 | B2 |
8503063 | Sprague | Aug 2013 | B2 |
8517958 | Eppstein et al. | Aug 2013 | B2 |
8520296 | Wang et al. | Aug 2013 | B2 |
8537104 | Markvoort et al. | Sep 2013 | B2 |
8565522 | Swic | Oct 2013 | B2 |
8570272 | Hsieh et al. | Oct 2013 | B2 |
8570639 | Masuzawa et al. | Oct 2013 | B2 |
8574937 | Shi | Nov 2013 | B2 |
8576470 | Paolini, Jr. et al. | Nov 2013 | B2 |
8576475 | Huang et al. | Nov 2013 | B2 |
8593721 | Albert et al. | Nov 2013 | B2 |
8599120 | Kanou | Dec 2013 | B2 |
8605354 | Zhang et al. | Dec 2013 | B2 |
8610998 | Baisch et al. | Dec 2013 | B2 |
8629832 | Tanabe | Jan 2014 | B2 |
8649084 | Wang et al. | Feb 2014 | B2 |
8670174 | Sprague et al. | Mar 2014 | B2 |
8674978 | Komatsu et al. | Mar 2014 | B2 |
8681191 | Yang et al. | Mar 2014 | B2 |
8687265 | Ahn et al. | Apr 2014 | B2 |
8696637 | Ross | Apr 2014 | B2 |
8704754 | Machida et al. | Apr 2014 | B2 |
8704756 | Lin | Apr 2014 | B2 |
8717662 | Komatsu | May 2014 | B2 |
8717664 | Wang et al. | May 2014 | B2 |
8744569 | Imran | Jun 2014 | B2 |
8786935 | Sprague | Jul 2014 | B2 |
8797258 | Sprague | Aug 2014 | B2 |
8797634 | Paolini, Jr. et al. | Aug 2014 | B2 |
8797636 | Yang et al. | Aug 2014 | B2 |
8797637 | Fujishiro et al. | Aug 2014 | B2 |
8810899 | Sprague et al. | Aug 2014 | B2 |
8830559 | Honeyman et al. | Sep 2014 | B2 |
8830561 | Zang et al. | Sep 2014 | B2 |
8862223 | Yanaki | Oct 2014 | B2 |
8873129 | Paolini, Jr. et al. | Oct 2014 | B2 |
8902153 | Bouchard et al. | Dec 2014 | B2 |
8902491 | Wang et al. | Dec 2014 | B2 |
8917439 | Wang et al. | Dec 2014 | B2 |
8962014 | Prinz et al. | Feb 2015 | B2 |
8964282 | Wang et al. | Feb 2015 | B2 |
8968699 | Jin et al. | Mar 2015 | B2 |
8976444 | Zhang et al. | Mar 2015 | B2 |
9013783 | Sprague | Apr 2015 | B2 |
9052564 | Sprague et al. | Jun 2015 | B2 |
9116412 | Lin | Aug 2015 | B2 |
9140952 | Sprague et al. | Sep 2015 | B2 |
9146439 | Zhang | Sep 2015 | B2 |
9164207 | Honeyman et al. | Oct 2015 | B2 |
9170467 | Whitesides et al. | Oct 2015 | B2 |
9170468 | Lin et al. | Oct 2015 | B2 |
9182646 | Paolini, Jr. et al. | Nov 2015 | B2 |
9186317 | Smyth et al. | Nov 2015 | B2 |
9188829 | Li et al. | Nov 2015 | B2 |
9195111 | Anseth et al. | Nov 2015 | B2 |
9199441 | Danner | Dec 2015 | B2 |
9251736 | Lin et al. | Feb 2016 | B2 |
9268191 | Paolini, Jr. et al. | Feb 2016 | B2 |
9285649 | Du et al. | Mar 2016 | B2 |
9293511 | Jacobson et al. | Mar 2016 | B2 |
9320720 | Maier | Apr 2016 | B2 |
9326979 | Kimura et al. | May 2016 | B2 |
9327105 | Ramdas et al. | May 2016 | B2 |
9341916 | Telfer et al. | May 2016 | B2 |
9360733 | Wang et al. | Jun 2016 | B2 |
9361836 | Telfer et al. | Jun 2016 | B1 |
9383623 | Lin et al. | Jul 2016 | B2 |
9388307 | Li | Jul 2016 | B2 |
9423666 | Wang et al. | Aug 2016 | B2 |
9459510 | Lin | Oct 2016 | B2 |
9460666 | Sprague et al. | Oct 2016 | B2 |
9513527 | Chan et al. | Dec 2016 | B2 |
9541814 | Lin et al. | Jan 2017 | B2 |
9610440 | Jordan et al. | Apr 2017 | B2 |
9671668 | Chan et al. | Jun 2017 | B2 |
9697778 | Telfer et al. | Jul 2017 | B2 |
9740076 | Paolini, Jr. et al. | Aug 2017 | B2 |
9759980 | Du et al. | Sep 2017 | B2 |
9812073 | Lin et al. | Nov 2017 | B2 |
9931296 | Doshi | Apr 2018 | B2 |
9968549 | Kosel et al. | May 2018 | B2 |
10036931 | Chan et al. | Jul 2018 | B2 |
10162242 | Wang et al. | Dec 2018 | B2 |
10209556 | Rosenfeld et al. | Feb 2019 | B2 |
10332435 | Wang et al. | Jun 2019 | B2 |
10514583 | Zhang | Dec 2019 | B2 |
10646454 | Liu et al. | May 2020 | B2 |
10918846 | Nagai et al. | Feb 2021 | B2 |
10933029 | Liu | Mar 2021 | B2 |
20010023330 | Palti | Sep 2001 | A1 |
20010035926 | Yamaguchi et al. | Nov 2001 | A1 |
20040085619 | Wu et al. | May 2004 | A1 |
20050191337 | Gueret | Sep 2005 | A1 |
20060009731 | Wu et al. | Jan 2006 | A1 |
20060257450 | Mudumba et al. | Nov 2006 | A1 |
20060269475 | Ryu et al. | Nov 2006 | A1 |
20070002008 | Tam | Jan 2007 | A1 |
20070080928 | Ishii et al. | Apr 2007 | A1 |
20070083186 | Carter | Apr 2007 | A1 |
20070196456 | Stevens et al. | Aug 2007 | A1 |
20070248657 | Smith et al. | Oct 2007 | A1 |
20070273637 | Zhou et al. | Nov 2007 | A1 |
20070292463 | Spector | Dec 2007 | A1 |
20080020007 | Zang | Jan 2008 | A1 |
20080042928 | Schlangen et al. | Feb 2008 | A1 |
20080043318 | Whitesides et al. | Feb 2008 | A1 |
20080048970 | Drzaic et al. | Feb 2008 | A1 |
20080062159 | Roh et al. | Mar 2008 | A1 |
20080117165 | Machida et al. | May 2008 | A1 |
20080174531 | Sah | Jul 2008 | A1 |
20090153942 | Daniel et al. | Jun 2009 | A1 |
20090167754 | Hatta | Jul 2009 | A1 |
20090184897 | Miyamoto | Jul 2009 | A1 |
20090225398 | Duthaler et al. | Sep 2009 | A1 |
20090234214 | Santini, Jr. et al. | Sep 2009 | A1 |
20090311484 | Mclellan et al. | Dec 2009 | A1 |
20100030129 | Nitzan et al. | Feb 2010 | A1 |
20100156780 | Jacobson et al. | Jun 2010 | A1 |
20100189793 | Meyer | Jul 2010 | A1 |
20100331811 | Imran | Dec 2010 | A1 |
20110043543 | Chen et al. | Feb 2011 | A1 |
20110046557 | Lee et al. | Feb 2011 | A1 |
20110111013 | Salman et al. | May 2011 | A1 |
20110175939 | Moriyama et al. | Jul 2011 | A1 |
20110196474 | Davalian et al. | Aug 2011 | A1 |
20110199671 | Amundson et al. | Aug 2011 | A1 |
20110217639 | Sprague | Sep 2011 | A1 |
20110234557 | Yang et al. | Sep 2011 | A1 |
20120299947 | Tsuda et al. | Nov 2012 | A1 |
20120326957 | Drzaic et al. | Dec 2012 | A1 |
20130096486 | Schroeder et al. | Apr 2013 | A1 |
20130242378 | Paolini, Jr. et al. | Sep 2013 | A1 |
20130278995 | Drzaic et al. | Oct 2013 | A1 |
20140009818 | Brochon et al. | Jan 2014 | A1 |
20140011913 | Du et al. | Jan 2014 | A1 |
20140055840 | Zang et al. | Feb 2014 | A1 |
20140078576 | Sprague | Mar 2014 | A1 |
20140330223 | Schurad et al. | Nov 2014 | A1 |
20140362213 | Tseng | Dec 2014 | A1 |
20150005720 | Zang | Jan 2015 | A1 |
20150018749 | Faupel | Jan 2015 | A1 |
20150118390 | Rosenfeld et al. | Apr 2015 | A1 |
20150167184 | Abhishek et al. | Jun 2015 | A1 |
20150241754 | Du et al. | Aug 2015 | A1 |
20150268531 | Wang et al. | Sep 2015 | A1 |
20150301246 | Zang et al. | Oct 2015 | A1 |
20150301425 | Du et al. | Oct 2015 | A1 |
20160045158 | Hsu | Feb 2016 | A1 |
20160048054 | Danner | Feb 2016 | A1 |
20160279072 | Li et al. | Sep 2016 | A1 |
20170121563 | Moran | May 2017 | A1 |
20170205649 | Wang et al. | Jul 2017 | A1 |
20180271799 | Liu et al. | Sep 2018 | A1 |
20180271800 | Liu et al. | Sep 2018 | A1 |
20180272114 | Liu et al. | Sep 2018 | A1 |
20190142763 | Liu | May 2019 | A1 |
20190143105 | Liu | May 2019 | A1 |
Number | Date | Country |
---|---|---|
1705907 | Dec 2005 | CN |
1457233 | Sep 2004 | EP |
2006343458 | Dec 2006 | JP |
2007033710 | Feb 2007 | JP |
2008033000 | Feb 2008 | JP |
2008209589 | Sep 2008 | JP |
2009116041 | May 2009 | JP |
2009192637 | Aug 2009 | JP |
2009244635 | Oct 2009 | JP |
2010044114 | Feb 2010 | JP |
2010210856 | Sep 2010 | JP |
2011158783 | Aug 2011 | JP |
19980025307 | Jul 1998 | KR |
20070082680 | Aug 2007 | KR |
20110103765 | Sep 2011 | KR |
20190122531 | Oct 2019 | KR |
201122697 | Jul 2011 | TW |
201237529 | Sep 2012 | TW |
1999053373 | Oct 1999 | WO |
2009073686 | Jun 2009 | WO |
Entry |
---|
“Magetically Triggered Reversible Controlled Drug Deliveyr form Microfabricated Polymeric Multireservoir Devices”, Cai et al., 2009. Advanced Materials. 21 (4045-4049). |
Seigou Kawaguchi et al., “Synthesis of polyethylene macromonomers and their radical copolymerizations with methyl methacrylate in homogeneous and oligoethylene melts media” Designed Monomers and Polymers 2000, vol. 3, No. 3, p. 263-277 Jan. 1, 2000. |
Korean Intellectual Property Office; PCT/US2015/011237; International Search Report and Written Opinion ; dated Apr. 10, 2015, dated Apr. 10, 2015. |
European Patent Office; EP Appl. No. 15737734.2; Extended European Search Report; dated Jun. 6, 2017, dated Jun. 6, 2017. |
European Patent Office, EP. Appl. No. 18772394.5, European Search Report, dated Nov. 30, 2020, dated Nov. 30, 2020. |
European Patent Office, EP. Appl. No. 18771792.1, Supplemental Partial European Search Report, dated Nov. 24, 2020, dated Nov. 24, 2020. |
European Patent Office, EP Appl. No. 18878337.7, Extended European Search Report, dated Feb. 8, 2021, dated Feb. 8, 2021. |
Korean Intellectual Property Office, PCT/US2020/061253, International Search Report and Written Opinion, dated Mar. 9, 2021, dated Mar. 9, 2021. |
European Patent Office, EP. Appl. No. 18771792.1, Extended European Search Report, dated Nov. 24, 2020, dated Mar. 31, 2021. |
Harvey, T.G.; “Replication techniques for micro-optics”; SPIE Proc. vol. 3099, pp. 76-82; 1997. |
Korean Intellectual Property Office, PCT/US2018/060259, International Search Report and Written Opinion, dated Apr. 29, 2019, dated Apr. 29, 2019. |
Ebbert Jon O. et al., “Combination Pharmacotherapy for Stopping Smoking: What Advantages Does it Offer?”, Drugs, vol. 70 No. 6, pp. 643-650, (Apr. 16, 2010). Apr. 16, 2010. |
Kaiyong Cai et al., “Magnetically triggered reversible Controlled Drug Delivery from Microfabricated Polymeric Multireservior Devices”., Advanced Materials. 2009, 21, 4045-4049 May 28, 2009. |
Korean Intellectual Property Office, PCT/US2018/023917, International Search Report and Written Opinion, dated Jul. 10, 2017, dated Jul. 10, 2018. |
Korean Intellectual Property Office, PCT/US2018/023928, International Search Report and Written Opinion, dated Jul. 10, 2018, dated Jul. 10, 2018. |
Korean Intellectual Property Office, PCT/US2018/023921, International Search Report and Written Opinion, dated Jul. 10, 2018, dated Jul. 10, 2018. |
Korean Intellectual Property Office, PCT/US2018/060266, International Search Report and Written Opinion, dated Apr. 29, 2019, dated Apr. 29, 2019. |
Xuan, Shouhu et al., “Systhesis of Fe3O4@Polyaniline Core/Shell Microspheres with Well-Defined Blackberrym-Like Morphology”, J. Phys. Chem. C., vol. 112, pp. 18804-18809. (2008). Oct. 3, 2008. |
Sahoo et al., “A Review of Transdermal drug delivery system”, Journal der Pharmazie Forschung, vol. 2, N-1, 2013, 32-56 (2013) 2013. |
Huang, W. C. et al . . . , “A flexible drug delivery chip for the magnetically-controlled release of anti-epileptic drugs”, Journal of Controlled Release, vol. 139, Issue 3, Nov. 3, 2009, pp. 221-228. |
European Patent Office, EP Appl. No. 18771343.3, Extended European Search Report, dated Aug. 14, 2020, dated Aug. 14, 2020. |
Gulati Gaurav Kumar et al., “Programmable carbon nanotube membrane-based transdermal nicotine delivery with microdialysis validation assay”, Nanomedicine: Nanotechnology, Biology and medicine, Elsevier, NL, vol. 13, No. 1, Jul. 18, 2016, p. 1-9, XP029879755, ISSN: 1549-9634 (Jul. 18, 2016) Jul. 18, 2016. |
Im J S et al., “The effect of carbon nanotubes on drug delivery in an electro-sensitive transdermal drug delivery system” Biomaterials, Elsevier, Amsterdam, NL, vol. 31, No. 6, Feb. 1, 2010, pp. 1414-1419, XP026814171, ISSN: 0142-9612 ( Feb. 1, 2020) Feb. 1, 2010. |
European Patent Office, “European Search Report”, EP Appl. No. 18879750.0, dated Jul. 27, 2021, dated Jul. 27, 2021. |
Number | Date | Country | |
---|---|---|---|
20190143105 A1 | May 2019 | US |
Number | Date | Country | |
---|---|---|---|
62585663 | Nov 2017 | US |